Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Remme

Showing results (161-170 of 236) with videos related to

Pageof 24
Sort By:
Journal of Cardiac Failure|April 21, 1998
Contrasting preload-dependent hemodynamic and neurohumoral effects of isomazole, a partial phosphodiesterase inhibitor and calcium sensitizerM Van der Ent, W J Remme, G L Bartels, et al.
Cardiovascular Drugs and Therapy|June 1, 1990
Duration and reproducibility of initial hemodynamic effects of flosequinan in patients with congestive heart failureG L Bartels, W J Remme, A C Wiesfeld, et al.
Cardiovascular Drugs and Therapy|April 30, 2004
The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN)Willem J Remme, Guenter Riegger, Per Hildebrandt, et al.
Tropical Medicine and Parasitology : Official Organ of Deutsche Tropenmedizinische Gesellschaft and of Deutsche Gesellschaft Fur Technische Zusammenarbeit (GTZ)|September 1, 1989
A community trial of ivermectin in the onchocerciasis focus of Asubende, Ghana. II. Adverse reactionsG De Sole, K Awadzi, J Remme, et al.
European Heart Journal|May 1, 1996
Economic aspects of treatment with captopril for patients with asymptomatic left ventricular dysfunction in The NetherlandsB C Michel, M J Al, W J Remme, et al.
European Heart Journal|February 25, 2006
Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of riskJaap W Deckers, Dick M Goedhart, Eric Boersma, et al.
Annals of Tropical Medicine and Parasitology|June 14, 2002
Onchocerciasis: the clinical and epidemiological burden of skin disease in AfricaM E Murdoch, M C Asuzu, M Hagan, et al.
Cardiovascular Drugs and Therapy|July 28, 2007
ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA trialM L Bots, W J Remme, T F Lüscher, et al.
Journal of the American College of Cardiology|November 27, 2007
The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trialJasper J Brugts, Eric Boersma, Michel Chonchol, et al.
Journal of Cardiovascular Pharmacology|April 29, 1998
Effects of epanolol, a selective beta1-blocker with intrinsic sympathomimetic activity, in patients with ischemic left ventricular dysfunctionA F Van Den Heuvel, M van der Ent, D J van Veldhuisen, et al.
Pageof 24

Showing results (161-170 of 236) with videos related to

Sort By:
Pageof 24
Journal of Cardiac Failure|April 21, 1998
Contrasting preload-dependent hemodynamic and neurohumoral effects of isomazole, a partial phosphodiesterase inhibitor and calcium sensitizerM Van der Ent, W J Remme, G L Bartels, et al.
Cardiovascular Drugs and Therapy|June 1, 1990
Duration and reproducibility of initial hemodynamic effects of flosequinan in patients with congestive heart failureG L Bartels, W J Remme, A C Wiesfeld, et al.
Cardiovascular Drugs and Therapy|April 30, 2004
The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN)Willem J Remme, Guenter Riegger, Per Hildebrandt, et al.
Tropical Medicine and Parasitology : Official Organ of Deutsche Tropenmedizinische Gesellschaft and of Deutsche Gesellschaft Fur Technische Zusammenarbeit (GTZ)|September 1, 1989
A community trial of ivermectin in the onchocerciasis focus of Asubende, Ghana. II. Adverse reactionsG De Sole, K Awadzi, J Remme, et al.
European Heart Journal|May 1, 1996
Economic aspects of treatment with captopril for patients with asymptomatic left ventricular dysfunction in The NetherlandsB C Michel, M J Al, W J Remme, et al.
European Heart Journal|February 25, 2006
Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of riskJaap W Deckers, Dick M Goedhart, Eric Boersma, et al.
Annals of Tropical Medicine and Parasitology|June 14, 2002
Onchocerciasis: the clinical and epidemiological burden of skin disease in AfricaM E Murdoch, M C Asuzu, M Hagan, et al.
Cardiovascular Drugs and Therapy|July 28, 2007
ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA trialM L Bots, W J Remme, T F Lüscher, et al.
Journal of the American College of Cardiology|November 27, 2007
The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trialJasper J Brugts, Eric Boersma, Michel Chonchol, et al.
Journal of Cardiovascular Pharmacology|April 29, 1998
Effects of epanolol, a selective beta1-blocker with intrinsic sympathomimetic activity, in patients with ischemic left ventricular dysfunctionA F Van Den Heuvel, M van der Ent, D J van Veldhuisen, et al.
Pageof 24